The U.S. Food and Drug Administration approved Oxbryta (voxelotor), a drug from Global Blood Therapeutics Inc. developed to treat sickle cell disease in adults and children 12 years or older.

Novartis AG won U.S. approval for the company’s experimental sickle cell disease drug Adakveo.

Johnson & Johnson filed for an approval from European regulators for the company’s two-dose experimental vaccine to protect against Ebola.

A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.

Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.

The world’s first Ebola vaccine was recommended for approval by European drug regulators in a move hailed by the World Health Organization (WHO) as a “triumph for public health.”

Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.

GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.

Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.

Merck announced today a $300,000 cash donation to support non-governmental organization partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa.